Chee-Chee H. Stucky, M.D.

Closed for Enrollment

• Collection of Tissue, Blood Samples, and/or Cystic Fluid in Patients with Benign, Premalignant and/or Malignant Gastrointestinal (GI) Disease Scottsdale/Phoenix, Ariz.

  The goal of this study is to establish and maintain a gastrointestinal disease biospecimen bank containing samples of neoplasms, normal tissue, blood and/or any other tissue or cystic fluid from patients undergoing a diagnostic or therapeutic procedure for gastrointestinal disease.

• UVA-PC-PD101: A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to investigate whether pembrolizumab (MK-3475 ) can be used safely during neoadjuvant treatment and can improve the body's immune response against pancreatic cancer. Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the U.S. Food and Drug Administration (FDA) for this purpose.